How we help hematopoietic stem cell transplant patients: HSCT provides a potentially curative option for some types of cancer, but it comes with the risk of GVHD. GVHD occurs when the transplanted immune system attacks the recipient’s body and is the leading cause of non-cancer death in stem cell transplant recipients. Roughly half of HSCT recipients develop acute GVHD and it is caused by the activation and trafficking of pathogenic T cells, which then go on to attack healthy tissue.

At Equillium, we leverage deep understanding of immunology and its role in disease to pioneer new products for severe autoimmune and inflammatory disorders. Our lead asset, itolizumab, targets the CD6-ALCAM signaling pathway, which plays a central role in the activity and trafficking of pathogenic effector T cells that drive inflammation. It is designed to treat aGVHD by preventing this aberrant T cell activity and is currently being evaluated in a pivotal phase 3 clinical trial in combination with corticosteroids to potentially enhancing early disease response.


Contact Information:

Kimberly Irvine
Head of Patient Advocacy
2223 Avenida De La Playa, Suite 108, La Jolla, CA 92037

E: kirvine@equilliumbio.com 
M: (708) 307-0155